Literature DB >> 36056218

Bailout left atrial appendage occluder for pulmonary vein isolation and electrical cardioversion in patients with atrial fibrillation and left atrial appendage thrombus: a pilot study.

Chin-Feng Tsai1,2, Pang-Shuo Huang3,4, Fu-Chun Chiu3, Jien-Jiun Chen3, Sheng-Nan Chang3,4, Jung-Cheng Hsu5, Su-Kiat Chua6, Hsiao-Liang Cheng7, Yi-Chih Wang4,8, Juey-Jen Hwang3,4,8, Chia-Ti Tsai9,10.   

Abstract

BACKGROUND: Cardioversion and catheter-based circumferential pulmonary vein isolation (CPVI) are established rhythm control treatment strategies for patients with atrial fibrillation (AF). However, these treatments are contraindicated for AF patients with a left atrial appendage (LAA) thrombus.
METHODS: We conducted the first-in-man case series study to evaluate the feasibility and safety of performing cardioversion or CPVI in AF patients with LAA thrombus immediately after implantation of LAA Occluder (LAAO) in a combined procedure. In our multi-center LAAO registry of 310 patients, 27 symptomatic and drug-refractory AF patients underwent a combined procedure of LAAO and CPVI, among whom 10 (mean age 68 ± 16 years, 6 men) having anticoagulant-resistant LAA thrombus received a bailout procedure of LAAO implantation first then CPVI, and the other 17 patients without LAA thrombus received CPVI first then LAAO for comparison.
RESULTS: The mean CHA2DS2-VASc score and HAS-BLED score were comparable between these two groups. In patients with LAA thrombus, we put carotid filters and did a no-touch technique, neither advancing the wire and sheath into the LAA nor performing LAA angiography. After LAAO implantation, the connecting cable was still connected to the occluder when cardioversion was performed. During CPVI, the occluder location was registered in the LA geometry by three-dimensional mapping to guide the catheter not to touch the LAAO. The procedure was successful in all the patients without intra-procedural complications. After a mean follow-up of 1.7 ± 0.7 years, there was no device embolization, peri-device leak ≧ 5 mm or stroke event in both groups. The AF recurrence rate was also similar between the two groups (P = 0.697).
CONCLUSION: We demonstrated that cardioversion or CPVI is doable in symptomatic AF patients with LAA thrombus if LAA was occluded ahead as a bailout procedure.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.

Entities:  

Keywords:  Circumferential pulmonary vein isolation; Electrical cardioversion; Left atrial appendage occluder; Left atrial appendage thrombus

Year:  2022        PMID: 36056218     DOI: 10.1007/s00392-022-02085-0

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   6.138


  40 in total

1.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial.

Authors:  Vivek Y Reddy; Horst Sievert; Jonathan Halperin; Shephal K Doshi; Maurice Buchbinder; Petr Neuzil; Kenneth Huber; Brian Whisenant; Saibal Kar; Vijay Swarup; Nicole Gordon; David Holmes
Journal:  JAMA       Date:  2014-11-19       Impact factor: 56.272

Review 2.  Left Atrial Appendage Occlusion with Amplatzer Cardiac Plug and Amplatzer Amulet: a Clinical Trials Update.

Authors:  Apostolos Tzikas
Journal:  J Atr Fibrillation       Date:  2017-12-31

Review 3.  Global epidemiology of atrial fibrillation.

Authors:  Faisal Rahman; Gene F Kwan; Emelia J Benjamin
Journal:  Nat Rev Cardiol       Date:  2014-08-12       Impact factor: 32.419

Review 4.  Atrial fibrillation.

Authors:  Gregory Y H Lip; Laurent Fauchier; Saul B Freedman; Isabelle Van Gelder; Andrea Natale; Carola Gianni; Stanley Nattel; Tatjana Potpara; Michiel Rienstra; Hung-Fat Tse; Deirdre A Lane
Journal:  Nat Rev Dis Primers       Date:  2016-03-31       Impact factor: 52.329

Review 5.  Left atrial appendage closure for thromboembolism prevention in patients with atrial fibrillation: advances and perspectives.

Authors:  Bin Kong; Yu Liu; He Huang; Hong Jiang; Congxin Huang
Journal:  J Thorac Dis       Date:  2015-02       Impact factor: 2.895

6.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).

Authors:  Vivek Y Reddy; Sven Möbius-Winkler; Marc A Miller; Petr Neuzil; Gerhard Schuler; Jens Wiebe; Peter Sick; Horst Sievert
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

7.  Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit.

Authors:  Sandeep R Gangireddy; Jonathan L Halperin; Valentin Fuster; Vivek Y Reddy
Journal:  Eur Heart J       Date:  2012-09-24       Impact factor: 29.983

8.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

9.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.

Authors:  Lucas V Boersma; Hueseyin Ince; Stephan Kische; Evgeny Pokushalov; Thomas Schmitz; Boris Schmidt; Tommaso Gori; Felix Meincke; Alexey Vladimir Protopopov; Timothy Betts; David Foley; Horst Sievert; Patrizio Mazzone; Tom De Potter; Elisa Vireca; Kenneth Stein; Martin W Bergmann
Journal:  Heart Rhythm       Date:  2017-05-31       Impact factor: 6.343

Review 10.  Atrial fibrillation: the current epidemic.

Authors:  Carlos A Morillo; Amitava Banerjee; Pablo Perel; David Wood; Xavier Jouven
Journal:  J Geriatr Cardiol       Date:  2017-03       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.